Abstract: The present disclosure relates to nanoparticles and the uses thereof in medicine, in particular in a method for treating cancer in a patient comprising in vivo capturing copper and/or iron in the patient by administering an effective amount of a colloidal solution of nanoparticles to said patient, and wherein the colloidal solution of nanoparticles is administered by intravenous, intratumoral or intrapulmonary injection, and wherein the nanoparticles have the following formula: [Ch1]n—PS—[Ch2]m, as described in the description.

Abstract: The present disclosure relates to a functionalized polymer, for use in treating a disease correlated with heavy metal-induced toxicity or heavy metal-induced carcinogenicity in a subject in need thereof, wherein said functionalized polymer is soluble in aqueous solution, has a weight average molecular mass between 30 kDa and 5000 kDa, and wherein a part of the monomeric units are functionalized with a chelating moiety, wherein therapeutically efficient amount of said functionalized polymer is administered orally to the subject.

Abstract: The present disclosure relates to a functionalized statistic chitosan of weight average molecular mass between 100 kDa and 1000 kDa and of formula (I): wherein each Rc is independently a moiety comprising a chelating agent, each Z is independently a linker which is a single bond or a hydrocarbon chain containing between 1 and 12 carbon atoms, said hydrocarbon chain is linear or branched and optionally contains one or more unsaturations and one or more heteroatoms, x is between 0.005 and 0.7, preferably between 0.05 and 0.7, y is between 0.01 and 0.7, preferably between 0.05 and 0.2, the ratio y/x being greater than or equal to 0.05, preferably greater than or equal to 0.15, and the sum x+y being greater than or equal to 0.15, for use in the treatment of diseases characterized by local inflammation induced by and/or inducing a deregulation of metal homeostasis and increased oxidative stress, in a subject in need thereof.

Abstract: A pharmaceutical formulation of a pharmaceutically active protein including an effective amount of a protein or a combination of proteins, a chitosan A and at least one statistic polysaccharide B. Also, a kit including the at least one first container containing the chitosan A and the statistic polysaccharide B and at least one second container containing the protein or combination of proteins. Further, the pharmaceutical formulation or the kit for use in the treatment of cancer, typically breast or gastric cancer.